NasdaqGS:MRNABiotechs
The Bull Case For Moderna (MRNA) Could Change Following New Data On Its Personalized Cancer Vaccine
Moderna recently presented at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 in Miami, highlighting progress across its mRNA vaccine and oncology pipeline, including regulatory filings for its influenza vaccine and advances in its personalized cancer vaccine program with Merck.
This combination of late-stage cancer vaccine data, broader infectious disease ambitions, and ongoing patent disputes with BioNTech is reshaping how investors assess the durability and breadth of...